Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Not applicableStudy completedNCT04207775
What this trial is testing

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
AstraZeneca 300
Not applicableUnknownNCT04930133
What this trial is testing

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Who this might be right for
NSCLC
Seoul St. Mary's Hospital 737
Testing effectiveness (Phase 2)UnknownNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06982924
What this trial is testing

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
Shanghai Chest Hospital 136
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106
What this trial is testing

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Who this might be right for
Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca 682
Testing effectiveness (Phase 2)Looking for participantsNCT06755684
What this trial is testing

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Who this might be right for
EGFRNon-Small Cell Lung CancerLocally Advanced Non-Small Cell Lung Cancer+5 more
Peng Zhang 60
Large-scale testing (Phase 3)Active Not RecruitingNCT03521154
What this trial is testing

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Who this might be right for
Non Small Cell Lung Cancer (Stage III)
AstraZeneca 216
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Testing effectiveness (Phase 2)UnknownNCT04978753
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerBrain Metastases
Li-kun Chen 54
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Large-scale testing (Phase 3)Looking for participantsNCT04853342
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc. 318
Early research (Phase 1)UnknownNCT03827070
What this trial is testing

Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non Small Cell Lung Cancer
Center Trials & Treatment Europe 12
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Testing effectiveness (Phase 2)UnknownNCT04643847
What this trial is testing

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Who this might be right for
EGFR Positive Non-small Cell Lung CancerBrain Metastases
First People's Hospital of Hangzhou 47
Next Page